CJC/IPA Protocol vs Thymosin Beta-4
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC/IPA Protocol and Thymosin Beta-4 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC/IPA Protocol Thymosin Beta-4
Weight N/A 4,963.44 Da
Half-life — Dose-dependent; relatively short (exact values not established)
Chain N/A 43 amino acids
Type Peptide combination (GHRH analog + GHS) Thymosin peptide
Key Benefits
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
CJC/IPA Protocol Thymosin Beta-4
Status Well Studied Well Studied
References 4 studies 4 studies
Latest June 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.